Celebrate more early results

INVOKANA® demonstrated reductions in A1C, body weight, and systolic BP as early as 12 weeks1,2

INVOKANA® is the only SGLT2i to demonstrate an A1C reduction of 1% from an average mean baseline of 8% (with 300 mg) at 26 weeks3*

Adjusted mean change from baseline in a monotherapy study1,2

 

INVOKANA® is not indicated for weight loss or as an antihypertensive treatment.

P<0.001.

§Confidence intervals are based on placebo-subtracted results.

  • Reductions from baseline at week 12 (prespecified endpoint)1,2:
    • INVOKANA® 100 mg: –0.72%
    • INVOKANA® 300 mg: –0.93%

*Based on monotherapy trials in the class.

BP=blood pressure; SGLT2i=sodium-glucose co-transporter 2 inhibitor.

The recommended starting dose of INVOKANA® is 100 mg once daily.1

Adjusted mean change from baseline in a monotherapy study1,2

 

INVOKANA® is not indicated for weight loss or as an antihypertensive treatment.

P<0.001.

§Confidence intervals are based on placebo-subtracted results.

  • Weight loss occurred early and progressed with INVOKANA® 300 mg for the remaining treatment period1,2

BP=blood pressure; SGLT2i=sodium-glucose co-transporter 2 inhibitor.

*Based on monotherapy trials in the class.

Prespecified secondary endpoint.

The recommended starting dose of INVOKANA® is 100 mg once daily.3

Adjusted mean change from baseline in a monotherapy study1,2

 

INVOKANA® is not indicated for weight loss or as an antihypertensive treatment.

P<0.001.

§Confidence intervals are based on placebo-subtracted results.

 

BP=blood pressure; SGLT2i=sodium-glucose co-transporter 2 inhibitor.

*Based on monotherapy trials in the class.

Prespecified secondary endpoint.

Monotherapy vs placebo + diet and exercise at 26 weeks (Stenlöf et al)

 

The efficacy and safety of INVOKANA® monotherapy were assessed in subjects with type 2 diabetes mellitus who were inadequately controlled with diet and exercise. In this 26-week, double-blind, placebo-controlled study, 584 patients were randomized to receive placebo (n=192), INVOKANA® 100 mg (n=195), or INVOKANA® 300 mg (n=197). Mean baseline A1C values were, respectively, 7.97%, 8.06%, and 8.01%. The primary endpoint was the change in A1C from baseline to week 26. Prespecified secondary endpoints included change in fasting plasma glucose, change in percent body weight, and change in systolic blood pressure.1,3

References: 1. Stenlöf K, Cefalu WT, Kim KA, et al. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab. 2013;15(4):372-382. 2. Data on file. Janssen Pharmaceuticals, Inc., Titusville, NJ. 3. INVOKANA® [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals, Inc.